0001193125-26-170888.txt : 20260423 0001193125-26-170888.hdr.sgml : 20260423 20260422173111 ACCESSION NUMBER: 0001193125-26-170888 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260420 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260423 DATE AS OF CHANGE: 20260422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Oncology Therapeutics, Inc. CENTRAL INDEX KEY: 0001869105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41955 FILM NUMBER: 26884859 BUSINESS ADDRESS: STREET 1: 256 E. GRAND AVENUE, SUITE 104 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 857 702 0377 MAIL ADDRESS: STREET 1: 256 E. GRAND AVENUE, SUITE 104 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Helix Acquisition Corp. II DATE OF NAME CHANGE: 20210623 8-K 1 d253464d8k.htm 8-K 8-K
false 0001869105 0001869105 2026-04-20 2026-04-20
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2026

 

 

BridgeBio Oncology Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-41955   39-3690783

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

256 E. Grand Avenue, Suite 104

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 405-4770

(Telephone number, including area code, of agent for service)

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   BBOT   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment Chief Executive Officer and Director

On April 20, 2026, the Board of Directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) approved the appointment of Pedro Beltran, Ph.D., as the Company’s President and Chief Executive Officer (“CEO”) (and as the Company’s principal executive officer), effective immediately. Dr. Beltran succeeds Eli Wallace, Ph.D. in these positions.

Additionally, on April 20, 2026, Dr. Wallace resigned from his position as a member of the Board and as a Class III director, and the Board appointed Dr. Beltran as a Class III director to fill the vacancy created by Dr. Wallace’s resignation, effective immediately. It is expected that Dr. Wallace will continue to serve as an advisor to the Company following his term as President and CEO. Dr. Wallace’s resignation was not the result of any disagreement with the policies, procedures or practices of the Company. The Board thanks Dr. Wallace for his years of service to the Company.

Dr. Beltran, age 55, served as Chief Scientific Officer of the Company (including the Company’s predecessor, TheRas, Inc.) since April 2024 until his appointment as President and CEO. Previously, Dr. Beltran served as Chief Scientific Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from July 2023 to April 2024, and as Senior Vice President of Biology from July 2020 to July 2023. From November 2017 to July 2020, Dr. Beltran was Senior Vice President, Head of Biology at UNITY Biotechnology and from 2003 to 2017 held various roles at Amgen, Inc., including Executive Director of Oncology Research. He has led multiple Investigational New Drug application submissions, authored more than 50 peer-reviewed articles, presented at numerous national and international scientific conferences, and holds diverse patents for the treatment of malignant diseases. Dr. Beltran completed postdoctoral work in Molecular and Cellular Pharmacology at the University of Miami, holds a Ph.D. in Cancer Biology from the University of Texas, MD Anderson Cancer Center, and a B.S. in Molecular Biology from Florida Institute of Technology.

Dr. Beltran is employed on an at-will basis pursuant to an employment agreement with the Company. Dr. Beltran is entitled to receive an annual base salary and an annual target bonus equal to a percentage of his annual base salary, subject to review and adjustment by the Board or the Compensation Committee thereof from time to time. Dr. Beltran is also eligible to receive equity awards and participate in the Company’s employee benefit plans, subject to the terms of such plans. In connection with his appointment as CEO, Dr. Beltran will become entitled to receive severance benefits pursuant to the Company’s Executive Severance Plan as a Tier 1 officer. Dr. Beltran continues to be subject to an existing proprietary information and inventions agreement with the Company. In connection with his appointment as a director, Dr. Beltran also entered into an amended and restated indemnification agreement in the form previously approved by the Board for the Company’s directors.

There are no arrangements or understandings between Dr. Beltran and any other person pursuant to which he was selected as a director, President and CEO. Dr. Beltran does not have any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Dr. Beltran and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

Appointment of Chief Operating Officer

On April 20, 2026, the Board also appointed Idan Elmelech as Chief Operating Officer of the Company, effective immediately.

Mr. Elmelech, age 33, served as Senior Vice President, Strategy and Business Development, of the Company (including its predecessor, TheRas, Inc.) from May 2024 until his promotion to Chief Operating Officer. Prior to this role, Mr. Elmelech was Director, Strategy and Business Development at BridgeBio Pharma, Inc. (Nasdaq: BBIO) from July 2023 to April 2024, where he led the $200 million equity financing and spinout of TheRas, Inc. From January 2021 to April 2023, Mr. Elmelech served as a consultant in the life science practice of L.E.K. Consulting, a global management consulting firm, and previously, spent time in early-stage biotechnology venture capital. Mr. Elmelech holds an MBA in Finance from Columbia Business School, an MA in Biotechnology from Columbia University and a BA in Economics and Psychology from Bard College.

 

Mr. Elmelech is employed on an at-will basis pursuant to an employment agreement with the Company. Mr. Elmelech is entitled to receive an annual base salary and an annual target bonus equal to a percentage of his annual base salary, subject to review and adjustment by the Board or the Compensation Committee thereof from time to time. Mr. Elmelech is also eligible to receive equity awards, to participate in the Company’s employee benefit plans, subject to the terms of such plans, and to receive severance benefits pursuant to the Company’s Executive Severance Plan as a Tier 2 officer. Mr. Elmelech continues to be subject to an existing proprietary information and inventions agreement with the Company. In connection with his promotion to Chief Operating Officer, Mr. Elmelech also entered into an officer indemnification agreement in the form previously approved by the Board for the Company’s executive officers.

There were no arrangements or understandings between Mr. Elmelech and any other persons pursuant to which Mr. Elmelech was selected as Chief Operating Officer. There are no family relationships between Mr. Elmelech and any director or executive officer of the Company, and there are no transactions between Mr. Elmelech and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

The foregoing summaries are qualified in their entirety by reference to the full text of (i) the Company’s Executive Severance Plan, which is filed as Exhibit 10.23 to the Company’s Current Report on Form 8-K filed on August 12, 2025; (ii) the Company’s form of director indemnification agreement, which is filed as Exhibit 10.26 to the Company’s Current Report on Form 8-K filed on August 12, 2025; and (iii) the Company’s form of officer indemnification agreement, which is filed as Exhibit 10.27 to the Company’s Current Report on Form 8-K filed on August 12, 2025, all of which are incorporated herein by reference.

Appointment of Executive Chairman

On April 20, 2026, the Board appointed Neil Kumar, Ph.D., as Executive Chairman of the Board, effective immediately. Jake Bauer, the Chairman of the Board, will continue to serve in such capacity.

Principal Financial Officer and Principal Accounting Officer Transitions

On April 21, 2026, Uneek Mehra, the Company’s Chief Financial Officer, departed from his roles as principal financial officer and principal accounting officer of the Company, and his last day with the Company will be April 30, 2026.

Effective April 21, 2026, the Company’s Board of Directors appointed Mr. Elmelech as the Company’s principal financial officer and Marc Cobo, the Company’s Vice President of Finance and Controller, as the Company’s principal accounting officer.

Mr. Elmelech’s biographical information and the terms of his employment with the Company are set forth above and incorporated herein by reference.

Mr. Cobo, age 46, has served as the Company’s Vice President of Finance and Controller since May 2025. From March 2021 to March 2024, Mr. Cobo served as Executive Vice President and Chief Accounting Officer of SFJ Pharmaceuticals, Inc. Prior to that, Mr. Cobo served as Senior Vice President of Finance and Chief Accounting Officer of Tricida, Inc. (formerly Nasdaq: TCDA), from June 2020 to December 2020. Mr. Cobo holds a B.A. in Accounting from the Santa Clara University Leavey School of Business and is a Certified Public Accountant in the State of California.

Mr. Cobo is employed on an at-will basis pursuant to an employment agreement with the Company. Mr. Cobo is entitled to receive an annual base salary and an annual target bonus equal to a percentage of his annual base salary, subject to review and adjustment by the Company from time to time. Mr. Cobo is also eligible to receive equity awards and participate in the Company’s employee benefit plans, subject to the terms of such plans. Mr. Cobo continues to be subject to an existing proprietary information and inventions agreement with the Company. In connection with his appointment as principal accounting officer, Mr. Cobo will enter into an indemnification agreement in the form previously approved by the Board for officers of the Company.

There are no arrangements or understandings between Mr. Elmelech or Mr. Cobo and any other person pursuant to which each was selected as principal financial officer and principal accounting officer, respectively. Neither Mr. Elmelech nor Mr. Cobo has any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Mr. Elmelech or Mr. Cobo and the Company that would be required to be reported under Item 404(a) of Regulation S-K

 

Item 7.01

Regulation FD Disclosure.

On April 22, 2026, the Company issued a press release regarding certain of the foregoing leadership transitions, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 991.1 shall not be deemed “filed” for any purpose, including for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

99.1    Press Release dated April 22, 2026
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
Date: April 22, 2026     By:  

/s/ Pedro Beltran

     

Name: Pedro Beltran

Title: President and Chief Executive Officer

 EX-99.1 2 d253464dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top executive

Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development

Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the Board of Directors to guide the company as it embarks on its next stage of development

Former CEO, Eli Wallace, PhD, will serve as a Senior Adviser to the company, continuing to leverage his scientific expertise and deep understanding of BBOT’s programs to support the company going forward

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer effective April 20th, 2026. This transition reflects BBOT entering a new phase of development as the company’s three clinical assets enter expansions and combinations across multiple RAS-driven cancers. The Board of Directors believes that elevating the next generation of BBOT’s leadership will enable the company to execute with strategic precision and purpose in order to improve outcomes for patients with RAS and PI3Kα malignancies.

“As BBOT’s programs enter Phase 1b expansions in multiple indications across the RAS and PI3Kα space, the company has recognized Pedro and Idan’s strategic vision, scientific acumen, and leadership capabilities to guide the company through its next phase of growth. BBOT is rapidly progressing towards pivotal trials to help more patients afflicted with some of the world’s deadliest cancers. This leadership transition is designed to accelerate and focus the development of BBOT’s programs and continue the company’s ethos of putting patients first,” said Neil Kumar, PhD, Executive Chairman of the Board of Directors.

LOGO

 

Dr. Kumar added, “The Board of Directors would like to thank Eli Wallace for his service to the company as CEO and looks forward to continuing to work with him in his new role as Senior Adviser.”

Dr. Beltran brings decades of experience in oncology drug development including 20 years with large pharmaceutical companies. Dr. Beltran joined BridgeBio Pharma in 2020 as Senior Vice President of Biology and became Chief Scientific Officer of BBOT in July 2023. Prior to BridgeBio, Dr. Beltran was Senior Vice President, Head of Biology at UNITY Biotechnology and Executive Director, Oncology Research at Amgen, Inc. Dr. Beltran has led multiple IND filings, authored more than 50 peer-reviewed articles, presented at multiple national/international scientific conferences, and holds diverse patents for the treatment of malignant diseases.

“I am energized and excited to step into the role of CEO as BBOT enters this important new chapter in its short trajectory. I am looking forward to continuing to partner with Idan, our Chief Medical Officer, Yong Ben, the board of directors, and the rest of our mission-driven BBOT team to focus our strategic execution in the pursuit of bringing fast and maximal benefit to patients from our novel therapies,” said Dr. Beltran.

Bihua Chen, Founder and Chief Executive Officer of Cormorant Asset Management and a BBOT director, said “We believe that BBOT is heading towards inflection points across its portfolio. This change in leadership reflects our goal to move with urgency to deliver returns for patients and investors alike.”

About BBOT

BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements, which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. We intend these forward-

LOGO

 

looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, including express or implied statements relating to the clinical and therapeutic potential of BBOT’s product candidates, BBOT’s plans to accelerate and focus the development of its programs, and the management team’s ability to execute on BBOT’s business strategy, are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including risks related to the timing of expected regulatory and business milestones, including interactions with regulatory authorities, the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials, changes in domestic and foreign business, market, financial, political, and legal conditions, and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.

In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.

BBOT Contacts:

Investor Contact:

Heather Armstrong, Head of Investor Relations

BBOT

Investors@BBOTx.com

Media Contact:

Totyana Simien

Inizio Evoke Comms

Totyana.Simien@inizioevoke.com

EX-101.SCH 3 bbot-20260420.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bbot-20260420_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 bbot-20260420_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g253464dsp5.jpg GRAPHIC begin 644 g253464dsp5.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information
Apr. 20, 2026
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001869105
Document Type 8-K
Document Period End Date Apr. 20, 2026
Entity Registrant Name BridgeBio Oncology Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41955
Entity Tax Identification Number 39-3690783
Entity Address, Address Line One 256 E. Grand Avenue
Entity Address, Address Line Two Suite 104
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 405-4770
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol BBOT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bbot-20260420.xsd bbot-20260420_lab.xml bbot-20260420_pre.xml d253464d8k.htm http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d253464d8k.htm": { "nsprefix": "bbot", "nsuri": "http://bbotx.com/20260420", "dts": { "schema": { "local": [ "bbot-20260420.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "bbot-20260420_lab.xml" ] }, "presentationLink": { "local": [ "bbot-20260420_pre.xml" ] }, "inline": { "local": [ "d253464d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 24 }, "report": { "R1": { "role": "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2026-04-20_to_2026-04-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d253464d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2026-04-20_to_2026-04-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d253464d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://bbotx.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-26-170888-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-26-170888-xbrl.zip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d253464d8k_htm.xml IDEA: XBRL DOCUMENT 0001869105 2026-04-20 2026-04-20 false 0001869105 8-K 2026-04-20 BridgeBio Oncology Therapeutics, Inc. DE 001-41955 39-3690783 256 E. Grand Avenue Suite 104 South San Francisco CA 94080 (650) 405-4770 false false false false Common Stock, par value $0.0001 per share BBOT NASDAQ true false